9 citations
,
March 1991 in “Endocrinology” This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.
January 2019 in “Oncogen” This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.
September 2025 in “Deleted Journal” This study found that in vitro environments simulating testosterone levels in elderly males, testosterone and its metabolite DHT significantly reduced macrophages' ability to phagocytize MRSA and Pseudomonas aeruginosa, suggesting AR manipulation and inhibiting testosterone-DHT conversion might help fight wound infections in the elderly.
This case report discusses a patient with female androgenetic alopecia and chronic telogen effluvium, emphasizing the importance of follicular unclogging to enhance treatment effectiveness, combining deep cleaning, caffeine application, physical stimulation, and lifestyle changes as an individualized, effective alternative to oral medications.
80 citations
,
January 1995 in “The American Journal of Medicine” Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.